The Delhi High Court has issued an interim order restraining Dr. Reddy’s Laboratories from manufacturing and selling its VENUSIA sunscreens with a label that includes the word “SUN”. The court’s decision comes in response to a lawsuit filed by Glenmark Pharmaceuticals, which claims that Dr. Reddy’s is infringing on its trademark rights.

Glenmark Pharmaceuticals had launched its own sunscreen product, SUNSTAR, in 2018, and had obtained a trademark registration for the mark “SUN” in relation to sunscreen products. The company claims that Dr. Reddy’s use of the word “SUN” on its VENUSIA sunscreens is likely to cause confusion among consumers and dilute the distinctiveness of Glenmark’s trademark.

The Delhi High Court has agreed with Glenmark’s arguments, observing that Dr. Reddy’s use of the word “SUN” on its products is likely to cause confusion among consumers, who may mistakenly believe that the VENUSIA sunscreens are connected to Glenmark’s SUNSTAR product. The court has therefore restrained Dr. Reddy’s from using the word “SUN” on its VENUSIA sunscreens, pending the outcome of the lawsuit.

The court’s order is a significant setback for Dr. Reddy’s, which had launched its VENUSIA sunscreens with the SUN label in an attempt to capitalize on the popularity of sunscreens in the Indian market. The company will now have to rebrand its products and remove the SUN label, which could result in significant losses and damage to its reputation.

The lawsuit highlights the importance of trademark protection in the pharmaceutical industry, where companies invest heavily in building their brands and trademarks. The Delhi High Court’s decision demonstrates that courts will take a strict view of trademark infringement, particularly in cases where there is a likelihood of confusion among consumers.

The case will now proceed to trial, where Glenmark will have to prove that Dr. Reddy’s use of the word “SUN” on its VENUSIA sunscreens constitutes trademark infringement. If the court ultimately rules in favor of Glenmark, Dr. Reddy’s could face significant damages and penalties for its alleged infringement. The case is being closely watched by the pharmaceutical industry, which is keen to see how the courts will interpret trademark laws in cases of alleged infringement.

Glenmark Pharmaceuticals Inc, USA, has launched Epinephrine Injection USP, a bioequivalent and therapeutically equivalent product to the reference listed drug manufactured by BPI Labs, LLC. The product is available in a 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial and is intended for the U.S. market. According to IQVIA sales data, the Epinephrine Injection market had annual sales of approximately USD 67.6 million for the 12 months ending October 2025. This launch expands Glenmark’s institutional product portfolio and reinforces its commitment to providing high-quality, affordable treatment options.

Glenmark Pharmaceuticals Limited is a prominent Indian multinational pharmaceutical company that has been in operation since 1977. The company has grown from its origins in generic medicines and active pharmaceutical ingredients (APIs) to become a research-led global healthcare organization with a presence in over 80 countries. Glenmark’s core therapeutic expertise includes respiratory, dermatology, oncology, cardiovascular, and anti-infective treatments, with multiple R&D centres and manufacturing facilities across India and internationally.

In recent years, Glenmark has diversified into innovative drug development and biosimilars, while maintaining a strong portfolio of branded generics in high-growth markets. The company has also entered strategic collaborations and licensing deals to advance novel therapies, particularly in oncology. Despite facing quality control challenges in some manufacturing facilities, Glenmark continues to pursue a transformation towards a more innovation-centric business model aimed at increasing its branded portfolio and long-term global competitiveness.

The launch of Epinephrine Injection USP is part of Glenmark’s strategy to strengthen its institutional channel presence and improve access to essential medicines. According to Marc Kikuchi, President and Business Head for North America at Glenmark, the launch supports the company’s commitment to providing high-quality, affordable treatment options. With its robust revenue growth and expanding demand in key markets such as North America and Europe, Glenmark is well-positioned to continue its growth and expansion in the global pharmaceutical market.

Glenmark Specialty S.A., a subsidiary of India-based Glenmark Pharmaceuticals, has entered into a licensing agreement with China’s Jiangsu Hansoh Pharmaceutical Group Co. for the oncology drug Aumolertinib. The agreement grants Glenmark exclusive rights to develop and commercialize Aumolertinib in several high-potential markets, including the Middle East, Africa, Southeast and South Asia, Australia, New Zealand, Russia, and the Caribbean. In return, Hansoh Pharma will receive an upfront payment of tens of millions of dollars, followed by potential milestone payments of over $1 billion, as well as tiered royalties on net sales.

Aumolertinib is a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) used to treat non-small cell lung cancer (NSCLC). The drug has already received marketing authorization in the UK and China, and has been approved for four indications in China. It is also marketed in the UK and Europe under the brand names Ameile and Aumseqa. The partnership strengthens Glenmark’s oncology strategy across these regions, providing access to a promising new treatment for patients with NSCLC.

The agreement marks a significant milestone for Hansoh Pharma, as Aumolertinib is the company’s first innovative drug to be approved in an overseas market. It is also the first China-developed EGFR-TKI to be launched internationally. The deal demonstrates the growing importance of partnerships between pharmaceutical companies to bring new treatments to market and expand their global reach. With the potential for milestone payments of over $1 billion, the agreement also highlights the significant value of innovative oncology treatments and the growing demand for effective therapies in this field. Overall, the partnership between Glenmark and Hansoh Pharma has the potential to bring a new and effective treatment option to patients with NSCLC in several regions, and marks an important step forward in the development of innovative oncology therapies.

Glenmark Pharmaceuticals Inc. has issued a recall of over 11,100 bottles of its blood pressure medication, Ziac, due to potential cross-contamination with another drug. The medication, which is used to treat high blood pressure, also known as hypertension, may contain ezetimibe, a drug used to treat high cholesterol. The recall was initiated after testing of reserve samples revealed the presence of ezetimibe.

The affected pills come in 2.5mg and 6.25mg doses and are packaged in 30-count, 100-count, and 500-count bottles. The recall includes specific lot numbers with expiration dates ranging from November 2025 to May 2026. According to the Food and Drug Administration (FDA), the recall is classified as Class III, meaning that the use or exposure to the product is not likely to cause adverse health consequences.

Bisoprolol/hydrochlorothiazide, the active ingredients in Ziac, work by blocking beta-1 receptors in the heart, allowing it to return to a regular heartbeat. The medication is commonly used to treat high blood pressure, a condition that affects millions of people worldwide.

The FDA has not provided guidance on what patients should do if their medication is affected by the recall. The Independent has reached out to the FDA and Glenmark Pharmaceuticals for comment, but so far, no further information has been provided. Patients who are taking Ziac and are concerned about the recall should consult with their healthcare provider or pharmacist for advice on what to do next.

The recall highlights the importance of ensuring the quality and safety of pharmaceutical products. Cross-contamination can occur during the manufacturing process, and it is crucial for pharmaceutical companies to have rigorous testing and quality control measures in place to prevent such incidents. The FDA and pharmaceutical companies must work together to ensure that medications are safe and effective for patients to use.

Glenmark Pharmaceuticals has significantly expanded its presence in the “High Latin America” region, which includes Mexico, Colombia, Ecuador, Peru, Central America, and the Caribbean, over the past four years. The company’s growth in this region has been driven by innovation, product launches, and operational efficiency. In Mexico, Glenmark has nearly tripled its revenue, doubled its workforce, and expanded its sales force in recent years. The company attributes its success to its strategic use of data analytics, which enables it to identify high-growth therapeutic niches and make informed investment decisions.

Glenmark is also leveraging digitalization and telemedicine to accelerate research and adoption of new therapies. The company has a strong portfolio in respiratory care, dermatology, and oncology, and is focusing on launching innovative products in these areas. In Mexico, Glenmark is a market leader in oral solids and nasal sprays for allergic rhinitis, and has recently launched a new product that reached the number three position in nasal spray combinations within 10 months.

The company’s growth strategy also involves forming strategic alliances and co-development projects. Glenmark has established partnerships with local and regional laboratories to commercialize its molecules, and has also entered into collaborations with major pharmaceutical companies such as AstraZeneca. These partnerships allow Glenmark to expand its therapeutic coverage and maintain a robust pipeline of new products.

Over the next three to five years, Glenmark plans to launch a range of new products in respiratory, dermatology, and oncology. The company is committed to continuing to innovate and launch differentiated products that provide physicians with expanded therapeutic options and improve patient outcomes. In terms of digitalization, Mexico is seen as a strategic hub with enormous potential, offering greater business certainty and scalability than other Latin American countries.

Regulatory trends in Latin America are also influencing access to specialized therapies, with agencies increasingly adopting accelerated approval pathways and recognizing approvals from high-surveillance markets. Glenmark is preparing for these trends by digitalizing its processes and improving its regulatory capabilities. The company’s advice to other pharmaceutical companies operating in Mexico is to identify market niches, continuous innovation, and align investment decisions with long-term objectives. Overall, Glenmark’s position in Latin America is strong, and the company is well-placed to continue growing and expanding its presence in the region.